<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003746</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 32/98</org_study_id>
    <secondary_id>SWS-SAKK-32/98</secondary_id>
    <secondary_id>EU-98074</secondary_id>
    <nct_id>NCT00003746</nct_id>
  </id_info>
  <brief_title>Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia</brief_title>
  <official_title>Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known if giving cladribine once a day is more
      effective than giving cladribine once a week in patients with hairy cell leukemia.

      PURPOSE: Randomized phase III trial to compare the effectiveness of cladribine given once a
      day to cladribine given once a week in treating patients with hairy cell leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the acute hematotoxicity and infection rate with daily and weekly administration
           of cladribine in patients with hairy cell leukemia.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two
      treatment arms.

        -  Arm I: Patients receive daily subcutaneous bolus injections of cladribine (2-CDA) for 5
           days (standard dose).

        -  Arm II: Patients receive weekly subcutaneous bolus injections of 2-CDA for 5 weeks.

      Patients showing complete or partial remission at evaluation on day 71 of the first treatment
      course do not receive any further treatment until relapse or disease progression is evident.

      Patients showing minor or no response on day 71 of the first treatment course receive a
      subsequent course of standard dose 2-CDA.

      Patients are followed every 3 months for 2 years, then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute hematotoxicity at 10 weeks following study treatment</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute infection rate at 10 weeks following study treatment</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital admission frequency and length at 10 weeks following study treatment</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood support at 10 weeks following study treatment</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>CDA day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDA week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-chlorodeoxyadenosine (CDA) daily</intervention_name>
    <description>Daily administration</description>
    <arm_group_label>CDA day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-chlorodeoxyadenosine weekly</intervention_name>
    <description>Weekly administration</description>
    <arm_group_label>CDA week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed classic form or prolymphocytic variant hairy cell leukemia
             (HCL)

          -  Newly diagnosed HCL or progressive disease after prior treatment

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  NCI 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

        Renal:

          -  Creatinine no greater than 2.3 mg/dL

        Other:

          -  HIV negative

          -  Not pregnant

          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or
             basal or squamous cell carcinoma of the skin

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since any prior therapy and recovered

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No concurrent cytoreductive therapy

          -  No prior cladribine

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhard Zenhaeusern, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Zenh√§usern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755.</citation>
    <PMID>19672771</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

